Evaxion A (EVAX) Asset Utilization Ratio (2025 - 2026)
Evaxion A posted quarterly Asset Utilization Ratio of 0.29 for Q1 2026, up 65.71% year-on-year from 0.17 in Q1 2025, and up 11.71% on a QoQ basis from 0.26 in Q4 2025.
Evaxion A (EVAX) has 2 years of Asset Utilization Ratio data on file, last reported at 0.29 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio rose 65.71% year-over-year to 0.29; the trailing twelve-month figure through Mar 2026 stood at 0.29 (up 65.71% YoY), and the FY2025 full-year result was 0.37, up 39.69% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.29, up from 0.26 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.29 in Q3 2025 and bottomed at 0.13 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.29 |
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | 0.29 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.17 |